Sign In
Buy SLNO
$53.01
+0 (+0%)
At Close: Jun 23, 2026
Soleno Therapeutics (SLNO) Drops Amid Critical Scorpion Report -- Hagens Berman
08:21am, Tuesday, 19'th Aug 2025
SAN FRANCISCO, Aug. 19, 2025 (GLOBE NEWSWIRE) -- On August 15, 2025, shares in Soleno Therapeutics, Inc. (NASDAQ: SLNO) experienced a significant drop following the release of a highly critical report
How Much Upside is Left in Soleno Therapeutics (SLNO)? Wall Street Analysts Think 43.15%
10:55am, Monday, 11'th Aug 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 43.2% in Soleno Therapeutics (SLNO). While the effectiveness of this highly sought-after metric is questionable
Here's Why Momentum in Soleno Therapeutics (SLNO) Should Keep going
09:51am, Monday, 11'th Aug 2025
Soleno Therapeutics (SLNO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Soleno Therapeutics, Inc. (SLNO) Q2 2025 Earnings Call Transcript
03:01am, Thursday, 07'th Aug 2025
Soleno Therapeutics, Inc. (NASDAQ:SLNO ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Anish Bhatnagar - Chairman, President, CEO & COO James H. MacKaness - CFO & Com
Soleno (SLNO) Q2 Revenue Jumps 30%
08:21pm, Wednesday, 06'th Aug 2025
Soleno (SLNO) Q2 Revenue Jumps 30%
Soleno Therapeutics, Inc. (SLNO) Reports Q2 Loss, Tops Revenue Estimates
06:11pm, Wednesday, 06'th Aug 2025
Soleno Therapeutics, Inc. (SLNO) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to a loss of $0.57 per share a year ago.
Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports Second Quarter 2025 Financial Results
04:01pm, Wednesday, 06'th Aug 2025
REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases,
Soleno Therapeutics, Inc. (SLNO) is a Great Momentum Stock: Should You Buy?
01:00pm, Friday, 25'th Jul 2025
Does Soleno Therapeutics, Inc. (SLNO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Can Soleno Therapeutics (SLNO) Climb 33.11% to Reach the Level Wall Street Analysts Expect?
10:56am, Wednesday, 23'rd Jul 2025
The mean of analysts' price targets for Soleno Therapeutics (SLNO) points to a 33.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement am
Soleno Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock
09:07am, Thursday, 10'th Jul 2025
REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (Nasdaq: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases
Soleno Therapeutics Announces Proposed $200 Million Public Offering of Common Stock
06:01am, Thursday, 10'th Jul 2025
REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (Nasdaq:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases,
Soleno Therapeutics Announces Preliminary Financial and Operational Results for the Second Quarter Ended June 30, 2025
06:00am, Thursday, 10'th Jul 2025
REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (Nasdaq: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases
Soleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference
08:00am, Friday, 20'th Jun 2025
Conference is the first-ever international meeting jointly hosted by the Prader-Willi Syndrome Association | USA, the Foundation for Prader-Willi Research, and the International Prader-Willi Syndrome
REDWOOD CITY, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases,
REDWOOD CITY, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today ann
